Pfizer pulls plug on PCSK9 inhibitor bococizumab
Pfizer is terminating its clinical development programme for investigational PCSK9 inhibitor bococizumab, which was being assessed by the firm for reducing cholesterol.
Read More
Tag: bococizumab
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
